Clinical implications of unnatural amino acids and amines.
D000588:Amines / Q000627:therapeutic use*; D000596:Amino Acids / Q000627:therapeutic use*; D000818:Animals; D001593:Benzyl Compounds / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D010134:Fenclonine / Q000627:therapeutic use; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D007210:Indoleacetic Acids / Q000652:urine; D008303:Malignant Carcinoid Syndrome / Q000188:drug therapy; D008750:Methyldopa / Q000494:pharmacology / Q000627:therapeutic use; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors; D010300:Parkinson Disease / Q000188:drug therapy; D010649:Phenylalanine / Q000627:therapeutic use; D010673:Pheochromocytoma / Q000188:drug therapy; D051381:Rats; D012694:Serine / Q000627:therapeutic use; D012895:Sleep, REM; D009435:Synaptic Transmission; D014364:Tryptophan / Q000037:antagonists & inhibitors; D014443:Tyrosine / Q000627:therapeutic use
D000588:Amines; D000596:Amino Acids; D001593:Benzyl Compounds; D006834:Hydrazines; D007210:Indoleacetic Acids; D014443:Tyrosine; D012694:Serine; D010649:Phenylalanine; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D014364:Tryptophan; D006899:Mixed Function Oxygenases; D002262:Carboxy-Lyases; D010134:Fenclonine